record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
unreviewed
frontiers / frontier
Finding bundle
back to staterecord state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding typeNo entity list is declared.
evidence
source-boundtheoretical · manual state transition
proof impact
packet context1 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
theoretical
conditions
Provenance
source title
COG ACNS0423 phase II trial
authors
reviewer:will-blair
ACNS0423 modest improvement over ACNS0126 (3-yr EFS 22% vs 11%, p=0.019 with addition of lomustine) demonstrates insufficient efficacy ceiling; survival rate still critically low despite incremental advance.
vs_d12f6af2146b9b97 · manual_curation
outgoing
vf_fdf73c97da49b959Both chemotherapy failures (TMZ-based ACNS0423 and anti-angiogenic PBTC-022) demonstrate mechanism-agnostic inadequacy
incoming
extends · vf_78a0cedf2d1cceb5
contradicts · vf_0bdcf4be725c614b
supports · vf_5d212e0a9caf0c4e
events
vev_5ea028411fbf2113finding.assertedManual finding added to frontier state
reviewer:will-blair · 2026-05-29
reviewable changes
vpr_75f8d6f324b8de53finding.addManual finding added to frontier state
applied · reviewer:will-blair · 2026-05-29
evaluations
No evaluation record targets this finding id.